1Mayo Clinic Neuro-Informatics Laboratory, Mayo Clinic, Rochester, Minnesota.
2Department of Neurological Surgery, Mayo Clinic, Rochester, Minnesota.
Neurosurg Focus. 2024 May;56(5):E9. doi: 10.3171/2024.2.FOCUS23927.
Chordomas are rare tumors of the skull base and spine believed to arise from the vestiges of the embryonic notochord. These tumors are locally aggressive and frequently recur following resection and adjuvant radiotherapy. Proton therapy has been introduced as a tissue-sparing option because of the higher level of precision that proton-beam techniques offer compared with traditional photon radiotherapy. This study aimed to compare recurrence in patients with chordomas receiving proton versus photon radiotherapy following resection by applying tree-based machine learning models.
The clinical records of all patients treated with resection followed by adjuvant proton or photon radiotherapy for chordoma at Mayo Clinic were reviewed. Patient demographics, type of surgery and radiotherapy, tumor recurrence, and other variables were extracted. Decision tree classifiers were trained and tested to predict long-term recurrence based on unseen data using an 80/20 split.
Fifty-three patients with a mean ± SD age of 55.2 ± 13.4 years receiving surgery and adjuvant proton or photon therapy to treat chordoma were identified; most patients were male. Gross-total resection was achieved in 54.7% of cases. Proton therapy was the most common adjuvant radiotherapy (84.9%), followed by conventional or external-beam radiation therapy (9.4%) and stereotactic radiosurgery (5.7%). Patients receiving proton therapy exhibited a 40% likelihood of having recurrence, significantly lower than the 88% likelihood observed in those treated with nonproton therapy. This was confirmed on logistic regression analysis adjusted for extent of tumor resection and tumor location, which revealed that proton adjuvant radiotherapy was associated with a decreased risk of recurrence (OR 0.1, 95% CI 0.01-0.71; p = 0.047) compared with photon therapy. The decision tree algorithm predicted recurrence with an accuracy of 90% (95% CI 55.5%-99.8%), with the lowest risk of recurrence observed in patients receiving gross-total resection with adjuvant proton therapy (23%).
Following resection, adjuvant proton therapy was associated with a lower risk of chordoma recurrence compared with photon therapy. The described machine learning models were able to predict tumor progression based on the extent of tumor resection and adjuvant radiotherapy modality used.
脊索瘤是一种罕见的颅底和脊柱肿瘤,据信起源于胚胎脊索的遗迹。这些肿瘤具有局部侵袭性,在切除和辅助放疗后常复发。由于质子束技术与传统光子放疗相比具有更高的精度水平,因此引入了质子治疗作为一种组织保护选择。本研究旨在通过应用基于树的机器学习模型比较接受质子与光子放疗的脊索瘤患者的复发率。
回顾了在梅奥诊所接受手术切除后接受辅助质子或光子放疗的脊索瘤患者的临床记录。提取患者人口统计学、手术和放疗类型、肿瘤复发和其他变量。使用 80/20 分割,基于未见数据训练和测试决策树分类器,以预测长期复发。
共确定了 53 例平均年龄为 55.2 ± 13.4 岁的患者,这些患者接受手术和辅助质子或光子治疗以治疗脊索瘤;大多数患者为男性。54.7%的病例达到了大体全切除。质子治疗是最常见的辅助放疗(84.9%),其次是常规或外照射放疗(9.4%)和立体定向放射外科(5.7%)。接受质子治疗的患者复发的可能性为 40%,明显低于接受非质子治疗的患者的 88%。这在调整肿瘤切除范围和肿瘤位置的逻辑回归分析中得到了证实,结果表明质子辅助放疗与降低复发风险相关(OR 0.1,95%CI 0.01-0.71;p = 0.047)与光子治疗相比。决策树算法预测复发的准确率为 90%(95%CI 55.5%-99.8%),接受大体全切除和辅助质子治疗的患者复发风险最低(23%)。
与光子治疗相比,手术后辅助质子治疗与脊索瘤复发风险降低相关。所描述的机器学习模型能够根据肿瘤切除范围和辅助放疗方式预测肿瘤进展。